-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the…
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination…
BILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing…
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued…
Canadians called to action as rising inflation and growing demand for essential services place unprecedented strain on small charitiesTORONTO, Sept.…
NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE…
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of…
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5…
SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to…
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not…